X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ORCHID PHARMA LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ORCHID PHARMA LTD ABBOTT INDIA/
ORCHID PHARMA LTD
 
P/E (TTM) x 39.8 0.1 30,457.8% View Chart
P/BV x 9.4 0.2 6,097.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
ORCHID PHARMA LTD
Sep-13
ABBOTT INDIA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs6,110194 3,149.5%   
Low Rs3,99635 11,417.1%   
Sales per share (Unadj.) Rs1,552.2276.5 561.5%  
Earnings per share (Unadj.) Rs188.8-79.2 -238.4%  
Cash flow per share (Unadj.) Rs196.4-43.5 -452.1%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.653.9 1,476.9%  
Shares outstanding (eoy) m21.2570.45 30.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.30.4 786.0%   
Avg P/E ratio x26.8-1.4 -1,851.4%  
P/CF ratio (eoy) x25.7-2.6 -976.2%  
Price / Book Value ratio x6.32.1 298.8%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3768,067 1,331.1%   
No. of employees `0003.32.8 118.6%   
Total wages/salary Rs m3,9372,527 155.8%   
Avg. sales/employee Rs Th9,929.36,956.1 142.7%   
Avg. wages/employee Rs Th1,185.1902.5 131.3%   
Avg. net profit/employee Rs Th1,207.7-1,993.0 -60.6%   
INCOME DATA
Net Sales Rs m32,98519,477 169.4%  
Other income Rs m1,170407 287.3%   
Total revenues Rs m34,15519,884 171.8%   
Gross profit Rs m5,2451,103 475.7%  
Depreciation Rs m1622,519 6.4%   
Interest Rs m385,227 0.7%   
Profit before tax Rs m6,215-6,236 -99.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,203-125 -1,759.3%   
Profit after tax Rs m4,012-5,580 -71.9%  
Gross profit margin %15.95.7 280.9%  
Effective tax rate %35.42.0 1,765.4%   
Net profit margin %12.2-28.7 -42.5%  
BALANCE SHEET DATA
Current assets Rs m22,65511,014 205.7%   
Current liabilities Rs m6,68132,060 20.8%   
Net working cap to sales %48.4-108.1 -44.8%  
Current ratio x3.40.3 987.1%  
Inventory Days Days6595 68.3%  
Debtors Days Days2934 86.9%  
Net fixed assets Rs m83529,440 2.8%   
Share capital Rs m213705 30.2%   
"Free" reserves Rs m16,7152,043 818.3%   
Net worth Rs m16,9283,800 445.5%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m24,16246,510 51.9%  
Interest coverage x163.7-0.2 -84,761.3%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.40.4 326.0%   
Return on assets %16.8-0.8 -2,205.5%  
Return on equity %23.7-146.9 -16.1%  
Return on capital %36.9-3.7 -989.1%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m3697,513 4.9%   
Fx outflow Rs m3,8075,649 67.4%   
Net fx Rs m-3,4381,865 -184.4%   
CASH FLOW
From Operations Rs m1,5271,682 90.8%  
From Investments Rs m-2,148-9,860 21.8%  
From Financial Activity Rs m-1,0246,644 -15.4%  
Net Cashflow Rs m-1,646-1,535 107.2%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.6 171.7%  
FIIs % 0.1 3.3 3.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.1 55.3 30.9%  
Shareholders   18,270 84,811 21.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SHASUN PHARMA  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFE  STERLING BIOTECH  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Trade Marginally Up; FMCG Sector Rallies(12:30 pm)

Stock markets in India are trading higher presently. Gains are largely seen in FMCG stocks and consumer durables' stocks.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9%

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jul 23, 2018 02:57 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS